1. Home
  2. EOI vs DSGN Comparison

EOI vs DSGN Comparison

Compare EOI & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest

EOI

Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest

HOLD

Current Price

$19.70

Market Cap

817.2M

Sector

Finance

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$12.54

Market Cap

853.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EOI
DSGN
Founded
N/A
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
817.2M
853.8M
IPO Year
2004
2021

Fundamental Metrics

Financial Performance
Metric
EOI
DSGN
Price
$19.70
$12.54
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$15.25
AVG Volume (30 Days)
55.1K
663.2K
Earning Date
01-01-0001
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$18.04
$5.28
52 Week High
$21.44
$17.25

Technical Indicators

Market Signals
Indicator
EOI
DSGN
Relative Strength Index (RSI) 42.57 33.60
Support Level $19.39 $11.65
Resistance Level $20.20 $13.54
Average True Range (ATR) 0.19 0.70
MACD -0.05 -0.38
Stochastic Oscillator 32.93 10.39

Price Performance

Historical Comparison
EOI
DSGN

About EOI Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest

Eaton Vance Enhanced Equity Income Fund offers mutual funds that invest across a wide array of equity, income, and alternative strategies. The primary investment objective of the fund is to provide current income, with a secondary objective of capital appreciation. The company's sector allocation includes: Information Technology, Communication Services, Financials, Consumer Discretionary, Healthcare, Industries, Consumer Staples, Energy, Real Estate, and Materials.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: